Kroger, Albertsons and others allege an unlawful monopoly in one legal case and aim to recover overcharges for a drug in ...

Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the ...

Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: ...

Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...

Takeda forecast annual operating profit to rise 39% to Y475.00 billion. It expects savings from its enterprise-wide efficiency program, significant declines in restructuring expenses and lower ...

With Teva entering the next stage of its sweeping restructuring plan, thousands of employees are slated to be let go from the ...

Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsLuis Sanay - Vice President, Investor ...

TOKYO -- Japanese drugmaker Takeda Pharmaceuticals will invest $30 billion in the U.S. over the next five years, CEO ...

Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R ...

Takeda’s Julie Kim argues that Trump’s idea to match drug prices to that of other countries could cost the industry up to $1 ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...